A plant hormone called 6-benzylaminopurine (BAP) significantly reduced weight in obese mice while improving their metabolic health, according to research published in Molecular Metabolism in 2026. Gram Research analysis shows BAP worked by suppressing appetite, converting regular fat into calorie-burning brown fat, and improving blood sugar control and liver function in both male and female mice. While these results are promising, BAP has not yet been tested in humans and remains a preclinical discovery requiring further development before potential clinical use.
Scientists discovered that a plant hormone called 6-benzylaminopurine (BAP), normally used to help crops grow, can help mice lose weight and improve their health. According to Gram Research analysis, when obese mice ate this compound, they lost significant weight, had better blood sugar control, and their bodies burned fat more efficiently. The hormone worked differently in male and female mice but achieved similar results in both. This finding is exciting because current obesity medications often have unwanted side effects, and BAP appears to work through a completely different mechanism that might offer a safer alternative for treating obesity in humans.
Key Statistics
A 2026 research article in Molecular Metabolism found that 6-benzylaminopurine (BAP), a plant hormone, induced significant weight loss in obese male and female mice through appetite suppression and enhanced fat burning.
According to the 2026 study, BAP improved multiple metabolic markers in obese mice including glucose tolerance, fasting blood glucose levels, and liver health while simultaneously converting regular fat tissue into metabolically active brown fat.
Research published in Molecular Metabolism in 2026 demonstrated that BAP works through different biological mechanisms in male versus female mice, suggesting sex-specific optimization may be important for future obesity treatments.
A 2026 preclinical study identified that BAP inhibits specific cellular signaling pathways (MEK/ERK) involved in appetite stimulation and fat metabolism, offering a novel mechanism of action compared to currently available obesity medications.
The Quick Take
- What they studied: Whether a plant growth hormone called BAP could help obese mice lose weight and improve their metabolic health on a high-fat diet
- Who participated: Male and female obese mice fed a high-fat diet, plus laboratory cell models from mice and humans to understand how BAP works
- Key finding: Mice given BAP experienced significant weight loss through multiple mechanisms: they ate less, their bodies burned more fat, and their metabolic health improved across multiple measures including blood sugar control and liver function
- What it means for you: This research suggests BAP could become a new obesity treatment option with fewer side effects than current medications, though human studies are still needed to confirm safety and effectiveness
The Research Details
Researchers tested BAP in multiple ways to understand how it works. First, they gave obese mice the compound by mouth and measured changes in weight, appetite, and metabolic markers like blood sugar and insulin levels. They also examined how BAP changed the structure of fat tissue and whether it converted regular fat into brown fat (which burns calories for heat). To understand the biological mechanisms, they used laboratory models of brain cells and fat cells from both mice and humans, studying which genes and signaling pathways BAP affected. Finally, they used advanced genetic sequencing to map exactly which molecular pathways BAP was targeting.
This multi-layered approach is important because it doesn’t just show that BAP causes weight loss—it reveals exactly how and why it works. Understanding the mechanism helps scientists predict whether it might work in humans and identify potential side effects. Testing in both male and female mice revealed that BAP works through different biological pathways in each sex, which is crucial information for developing treatments that work equally well for everyone.
The study used established animal models of obesity and included both in-vivo (whole animal) and in-vitro (cell culture) experiments, which strengthens confidence in the findings. The use of RNA sequencing to identify molecular mechanisms adds scientific rigor. However, this is preclinical research—meaning it hasn’t yet been tested in humans. The study was published in a peer-reviewed journal (Molecular Metabolism), which means other scientists reviewed it before publication. The main limitation is that results in mice don’t always translate to humans, and the specific sample sizes for each experiment weren’t detailed in the abstract.
What the Results Show
Mice that received BAP lost significant weight compared to control mice on the same high-fat diet. This weight loss occurred through multiple mechanisms working together: the mice ate less food (appetite suppression), their bodies converted regular white fat into metabolically active brown fat that burns calories, and they used stored fat more efficiently for energy. Importantly, these effects occurred in both male and female mice, though the underlying biological mechanisms differed between sexes. The weight loss was accompanied by improvements in several markers of metabolic health: fasting blood glucose decreased, glucose tolerance improved (meaning their bodies handled sugar better), and abnormally high levels of leptin and insulin normalized. Additionally, liver health improved, which is significant because obesity often damages the liver.
Beyond weight loss, BAP improved overall metabolic function in multiple ways. The compound reduced hyperleptinemia (abnormally high leptin levels, a hormone that signals fullness) and hyperinsulinemia (abnormally high insulin levels, which can lead to diabetes). BAP also induced white adipose tissue browning—converting regular fat into brown fat that generates heat and burns calories. In brain cell models, BAP reduced expression of neuropeptide Y (a chemical that stimulates hunger) while increasing pro-opiomelanocortin (a chemical that suppresses appetite), explaining why the mice ate less. At the molecular level, BAP inhibited specific signaling pathways (EGFR/ErbB2 and MEK/ERK/EGR1) that are involved in both appetite regulation and fat metabolism.
Current obesity medications work through different mechanisms—some increase feelings of fullness, others reduce fat absorption, and some affect brain chemistry. BAP’s mechanism is novel because it simultaneously targets appetite suppression, fat tissue remodeling, and metabolic efficiency through inhibition of specific growth factor signaling pathways. This multi-targeted approach differs from single-mechanism drugs currently available. The finding that BAP works through different pathways in males versus females aligns with emerging research showing that obesity treatments may need sex-specific optimization. Unlike some current medications that have significant cardiovascular or psychiatric side effects, BAP’s mechanism suggests it might have a better safety profile, though this requires human testing.
This research was conducted entirely in mice and cell cultures—it has not been tested in humans yet. Animal studies often don’t translate directly to humans due to differences in metabolism and physiology. The abstract doesn’t specify exact sample sizes for each experiment, making it difficult to assess statistical power. The study doesn’t address potential long-term safety concerns or whether tolerance to BAP might develop with extended use. It’s unclear whether BAP would work in people with different genetic backgrounds or comorbid conditions. Additionally, the study used a specific type of high-fat diet; results might differ with other dietary patterns. Finally, BAP is currently used as an agricultural chemical, and its safety profile for human consumption hasn’t been established.
The Bottom Line
This research is promising but preliminary. Currently, BAP cannot be recommended for human use to treat obesity because it hasn’t been tested in people. The appropriate next step is clinical trials in humans to confirm safety and effectiveness. People with obesity should continue working with healthcare providers using currently approved treatments. However, this research may eventually lead to new treatment options, particularly for people who don’t tolerate or respond to existing medications. Confidence level: Low for human application (preclinical stage); High for the quality of the animal research.
This research is most relevant to obesity researchers, pharmaceutical companies developing new treatments, and people with obesity who have limited options due to side effects from current medications. It’s also relevant to endocrinologists and metabolic health specialists. People without obesity don’t need to act on this information. This research is not yet applicable to clinical practice.
In the mice studied, weight loss and metabolic improvements occurred within the timeframe of the experiments (specific duration not stated in abstract). If BAP advances to human trials, it would typically take 5-10 years of research before becoming available as a treatment. Even then, it would need regulatory approval and further safety monitoring.
Frequently Asked Questions
Can I use 6-benzylaminopurine to lose weight right now?
No, BAP is not approved for human use and hasn’t been tested in people. This 2026 research is preclinical—the first step in drug development. It would take years of human clinical trials before BAP could potentially become an available treatment.
How does this plant hormone help mice lose weight?
BAP works through three main mechanisms: it reduces appetite by changing brain chemicals that control hunger, it converts regular fat into brown fat that burns calories for heat, and it improves how the body uses stored fat for energy. These effects occurred in both male and female mice.
Why is this research important if it’s only been tested in mice?
This research identifies a completely new mechanism for treating obesity that’s different from current medications. Understanding how BAP works at the molecular level helps scientists determine whether it might work in humans and what side effects to monitor in future clinical trials.
Could BAP be safer than current obesity medications?
Possibly—BAP’s mechanism suggests it might avoid some side effects of current drugs. However, safety can only be confirmed through human testing. The 2026 study shows promise but doesn’t prove BAP is safe for people.
When will BAP be available as an obesity treatment?
If development proceeds, human clinical trials would likely begin within a few years, but regulatory approval and availability could take 5-10 years or longer. There’s no guarantee BAP will ever become an approved treatment.
Want to Apply This Research?
- Users interested in obesity research could track their current weight, appetite levels (1-10 scale), energy expenditure during exercise, and fasting blood glucose if available, creating a baseline for comparison if BAP or similar treatments become available in the future
- While BAP isn’t yet available, users can implement the appetite-suppression benefits the research identified by tracking hunger cues, eating slowly, and monitoring satiety. Users could also track brown fat activation through cold exposure exercises (which naturally activate brown fat) and monitor metabolic markers like fasting glucose through their healthcare provider
- Set up monthly tracking of weight, waist circumference, energy levels, and appetite patterns. If BAP becomes available through clinical trials, users could compare their baseline metrics to post-treatment measurements. Users should also monitor any metabolic markers their doctor measures (glucose, insulin, liver enzymes) to track overall metabolic health improvements
This research is preclinical and has not been tested in humans. 6-benzylaminopurine is not approved for human consumption and should not be used to treat obesity or any medical condition. This article is for educational purposes only and does not constitute medical advice. Anyone with obesity should consult with a healthcare provider about evidence-based treatment options currently available. Do not attempt to obtain or use BAP outside of authorized clinical research settings. Future human studies are needed to determine safety, efficacy, and appropriate dosing before this compound could potentially be considered for medical use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.